Your browser doesn't support javascript.
loading
Potential efficacy of T and B lymphocyte-targeted therapies on articular involvement of patients with rheumatoid arthritis and systemic sclerosis overlap syndrome. Results from a 2-centre series of 22 cases.
Lebel, Nans; Marie, Isabelle; Grosjean, Julien; Brevet, Pauline; Leclercq, Mathilde; Dumont, Anaël; Levesque, Hervé; Benhamou, Ygal; Marcelli, Christian; Lequerre, Thierry; Vittecoq, Olivier.
Affiliation
  • Lebel N; Department of Rheumatology, Rouen University, CHU de Rouen, and CIC-CRB 1404, Inserm 1234, Rouen, France.
  • Marie I; Department of Internal Medicine, Rouen University, CHU de Rouen, and Inserm 1234, Rouen, France.
  • Grosjean J; Department of Biomedical Informatics, Rouen University, CHU de Rouen, and LIMICS U1142, Sorbonne University, Paris, France.
  • Brevet P; Department of Rheumatology, Rouen University, CHU de Rouen, and CIC-CRB 1404, Inserm 1234, Rouen, France.
  • Leclercq M; Department of Internal Medicine, Rouen University, CHU de Rouen, and Inserm 1234, Rouen, France.
  • Dumont A; Department of Internal Medicine, Normandie Univ, UNICAEN, CHU de Caen, France.
  • Levesque H; Department of Internal Medicine, Rouen University, CHU de Rouen, and Inserm 1234, Rouen, France.
  • Benhamou Y; Department of Internal Medicine, Rouen University, CHU de Rouen, and Inserm 1234, Rouen, France.
  • Marcelli C; Department of Rheumatology, Normandie Univ, UNICAEN, CHU de Caen, France.
  • Lequerre T; Department of Rheumatology, Rouen University, CHU de Rouen, and CIC-CRB 1404, Inserm 1234, Rouen, France.
  • Vittecoq O; Department of Rheumatology, Rouen University, CHU de Rouen, and CIC-CRB 1404, Inserm 1234, Rouen, France. vittecoq.olivier@wanadoo.fr.
Clin Exp Rheumatol ; 2024 03 13.
Article in En | MEDLINE | ID: mdl-38489323
ABSTRACT

OBJECTIVES:

To analyse in routine practice the efficacy of targeted therapies on joint involvement of patients with rheumatoid arthritis/systemic sclerosis (RA/SSc) overlap syndrome.

METHODS:

This was a retrospective analysis of medical records of two academic centres over a 10-year period. Joint response to targeted therapies was measured according to EULAR criteria based on Disease Activity Score (DAS)-28. In addition, changes in CRP level and glucocorticoid consumption were recorded.

RESULTS:

Nineteen patients were included. Methotrexate (n=11) and hydroxychloroquine (n=4) were the most used first-line treatments. Targeted therapies were frequently used (n=14). Tocilizumab was the most selected therapy (n=8), then rituximab (n=5), abatacept and anti-tumour necrosis factor (n=4). Twenty-one treatment sequences were assessed, including 18 with EULAR response criteria. Responses were "good" or "moderate" in 100% (4/4) of patients treated with abatacept, 80% (4/5) with rituximab, 40% (2/5) with tocilizumab, and 25% (1/4) with anti-TNF. T and B lymphocyte-targeted therapies (abatacept, rituximab) resulted more frequently in a "good" or "moderate" response compared to cytokine inhibitors (tocilizumab, etanercept, infliximab) with a significant decrease in DAS-28 at 6 months (-1.75; p=0.016) and a trend to a lower consumption of glucocorticoids. C

CONCLUSIONS:

In patients with RA/SSc overlap syndrome refractory to conventional synthetic-DMARDs, T and B lymphocyte-targeted therapies seem to be a promising therapeutic option to control joint activity.

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Clin Exp Rheumatol Year: 2024 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Clin Exp Rheumatol Year: 2024 Document type: Article Affiliation country: